lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]
lithium carbonate
RxCUI: 206786
What the CMS Formulary Data Shows for lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]
Per the CMS 2026 Part D formulary file, lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] (RxNorm concept RXCUI 206786, generic name lithium carbonate) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 103,265 Part D beneficiaries filled lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] in 2023, with total plan-and-beneficiary spending of $7,437,848 and an average per-beneficiary annual cost of $72.03. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 2
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 103,265
- Total spending
- $7,437,848
- Avg per beneficiary
- $72.03
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]
2 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
Frequently Asked Questions
Is lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] covered by Medicare Part D?
Yes, lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] is covered by 2 Medicare Part D plans (0% of all Part D formularies).
What tier is lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] on Medicare Part D plans?
lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] require prior authorization?
0% of Part D formularies require prior authorization for lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]?
In 2023, total Medicare Part D spending on lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] was $7,437,848, covering 103,265 beneficiaries. The average spend per beneficiary was $72.03.
Read our methodology - how this data is sourced, computed, and verified.